GlycoMimetics Q3 cash $101.9M; uproleselan Phase 3 enrollment nearing completion

CRESCENT BIOPHARMA, INC.

2022-Q3 EPS reported -$0.90 revenue$1,142,142

Cash and cash equivalents $101.9M at Sept 30, 2021, down from $137.0M at Dec 31, 2020.
R&D expenses increased to $13.3M from $10.7M YoY, driven by Phase 3 trial costs.
Phase 3 trial of uproleselan in relapsed/refractory AML nearing enrollment completion; top line data after 2022.
Data published in BLOOD showed 69% MRD negative rate in evaluable relapsed/refractory AML patients.
New CEO Harout Semerjian appointed effective August 6, 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.